Literature DB >> 20427614

Bone marrow dysfunction in chronic heart failure patients.

B Daan Westenbrink1, Adriaan A Voors, Rudolf A de Boer, Jan J Schuringa, Theo Klinkenberg, Pim van der Harst, Edo Vellenga, Dirk J van Veldhuisen, Wiek H van Gilst.   

Abstract

AIMS: To investigate whether chronic heart failure (CHF) is associated with a general dysfunction of the haematopoietic compartment. METHODS AND
RESULTS: Bone marrow was obtained during coronary artery bypass graft surgery from 20 patients with CHF (age 67 +/- 6 years, 75% NYHA class >or= III, LVEF 32 +/- 6%), and 20 age- and gender-matched control patients with normal cardiac function. CD34(+) haematopoietic progenitor cells were isolated and cultured with increasing doses of erythropoietin (0.02-10 IU/mL, EPO), myeloid growth factors or a mix of both. After 14 days, burst forming units erythroid (BFU-E), and granulocyte or monocyte colony forming units (CFU-G, CFU-M, respectively) were counted. Apoptosis and erythropoietin-receptor (EPO-R) density were quantified by flow cytometry. Throughout the EPO dose range, the CD34(+) cells from CHF patients produced a two-fold lower number of BFU-E colonies compared with controls (P = 0.02). The resistance to EPO was associated with markedly increased apoptosis during erythroid differentiation in CHF patients compared with controls [5.3% (2.9-8.1%) vs. 1.5% (0.8-3.4%), P = 0.01]. Erythropoietin-receptor expression was, however, comparable between CHF patients and controls and the anti-apoptotic cytokine interleukin-3 did not rescue erythropoiesis. In the myeloid cultures, the number of CFU-G and CFU-M colonies was also two-fold lower in CHF patients compared with controls (both P < 0.01). In the mixed-culture assay, myelopoiesis and erythropoiesis were reduced to a similar magnitude in CHF patients. The impaired clonogenic potential was independently associated with clinical and biochemical severity of CHF, but not with the presence of anaemia.
CONCLUSION: Chronic heart failure is associated with profound and general bone marrow dysfunction, simultaneously affecting multiple haematopoietic lineages.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427614     DOI: 10.1093/eurjhf/hfq061

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  30 in total

1.  Acute short-term hyperoxia followed by mild hypoxia does not increase EPO production: resolving the "normobaric oxygen paradox".

Authors:  Tadej Debevec; Michail E Keramidas; Barbara Norman; Thomas Gustafsson; Ola Eiken; Igor B Mekjavic
Journal:  Eur J Appl Physiol       Date:  2011-07-07       Impact factor: 3.078

2.  Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients.

Authors:  Lennaert Kleijn; B Daan Westenbrink; Vincent M van Deursen; Kevin Damman; Rudolf A de Boer; Hans L Hillege; Dirk J van Veldhuisen; Adriaan A Voors; Peter van der Meer
Journal:  Clin Res Cardiol       Date:  2014-02-08       Impact factor: 5.460

Review 3.  Erythropoietin: a future therapy for failing hearts?

Authors:  Lindsey Tilling; Brian Clapp
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

Review 4.  Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

Authors:  Marcelo Perim Baldo; Sérgio Lamêgo Rodrigues; José Geraldo Mill
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

Review 5.  Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.

Authors:  Dirk J van Veldhuisen; Stefan D Anker; Piotr Ponikowski; Iain C Macdougall
Journal:  Nat Rev Cardiol       Date:  2011-05-31       Impact factor: 32.419

6.  Chronic restraint stress after injury and shock is associated with persistent anemia despite prolonged elevation in erythropoietin levels.

Authors:  Letitia E Bible; Latha V Pasupuleti; Amy V Gore; Ziad C Sifri; Kolenkode B Kannan; Alicia M Mohr
Journal:  J Trauma Acute Care Surg       Date:  2015-07       Impact factor: 3.313

Review 7.  Anemia in chronic heart failure: can we treat? What to treat?

Authors:  Stephan von Haehling; Markus S Anker; Ewa A Jankowska; Piotr Ponikowski; Stefan D Anker
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

Review 8.  Co-morbidities in heart failure.

Authors:  Vincent M van Deursen; Kevin Damman; Peter van der Meer; Peter J Wijkstra; Gert-Jan Luijckx; Andre van Beek; Dirk J van Veldhuisen; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

Review 9.  Iron deficiency anemia in heart failure.

Authors:  Natasha P Arora; Jalal K Ghali
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

10.  Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).

Authors:  John J V McMurray; Inder S Anand; Rafael Diaz; Aldo P Maggioni; Christopher O'Connor; Marc A Pfeffer; Scott D Solomon; Michal Tendera; Dirk J van Veldhuisen; Moetaz Albizem; Sunfa Cheng; Debra Scarlata; Karl Swedberg; James B Young
Journal:  Eur J Heart Fail       Date:  2013-01-17       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.